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Abstract
The preparation and characterization of two triorganophosphinegold(I) complexes containing the anion
derived from thiobenzoic acid are described. The cytotoxicity of these complexes has been
investigated along with that of triphenylphosphinegold(I) mercaptopurinate, a known anti-tumor
compound, against a variety of human cell fines. The complexes showed moderate to high cytotoxicity
(ID50 250 25(X) ng/ml).
Introduction
Auranof’m (triethylphosphinegold(I) tetraacetatothioglueose), featuring a linear P-Au-S arrangement, is
used clinically in the treatment of rheumatoid arthritis [1 3]. Auranof’m and analogues also possess
cytotoxieity and anti-tumor activity [4- 9]. Consequently, research into the potential anti-tumor
activity of systems related to aumnofm has attracted considerable attention [9]. A particularly
interesting series of complexes are those containing biologically active thiols such as 6-
mercaptopurine. Previous studies have shown that potency is found in cisplatin-resistant cell lines and
that activity is maintained in vivo [10 14]. This contribution reports the cytotoxicity of two
complexes, [Cy3PAu(SC(O)Ph)] (1) and [Ph3PAu(SC(O)Ph)] (2), containing the anion derived from
thiobenzoic acid against a panel of seven human cancer lines. For comparison, the eytotoxicity of
[Ph3PAu(6-MP)], isolated as an ethanol solvate and a known anti-rumor compound [12], is also
reported.
Experimental
General: IR spectra were recorded as KBr disks on a Perkin-Elmer FT-IR spectrophotometer. H, and
3C spectra were measured on a Varian Gemini-200 FT/spectmmeter operating at 199.953 and 50.283
MHz, respectively, and 3p NMR were measured on a Varian Gemini 2000 spectrometer operating at
121.501 MHz. Spectra were referenced to TMS or solvent where appropriate. Analytical grade
solvents were used without further purification. HAuCla [15] and R3PAuC1 [16] were prepared
according to the literature procedures. Thiobenzoic acid (Aldrich) was used without further
purification.
Synthesis: The preparations of the colorless gold complexes were in accord with established literature
methods 11, 12, 17].
4 3
Figure 1. Numbering scheme for thiobenzoic acid.
[Cy3PAu(SC(O)Ph)] (1) Yield 87 %, m. p. 190 191 C. IR: ,(C=O) 1620 crnq. NMR: H 8 8.15 (br,
2H, H3; see Figure for atom numbering scheme); 7.39 (br, 2H, H4); 7.48 (br, 1H, H5); 2.21 1.31
ppm (Cy-H). ’C 6 201.9, 142.9, 129.6, 128.4, 131.5 (C1 -C5); 34.2 (d, 27.9 Hz, Ca), 27.2 (d, 11.9
31 Hz, CI); 31.5 (Ct), 26.6 ppm (C6). P 8 57.0 ppm.
[Ph3PAu(SC(O)Ph)] (2) Yield 69 %, m. p. 148 150 C. IR: v(C=O) 1611 cm"1. NMR: 1H 6 8.13 (br,
2H, H3); 7.65 7.34 ppm (m, 18H, H4, H5 and Ph-H). 13C 6 201.1,142.0, 128.4, 127.8, 131.7 (C1
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C5); 129.4 (d, 58.4 Hz, Ca), 134.3 (d, 13.8 Hz, CI); 129.2 (d, 11.4 Hz, Ct), 131.7 ppm (C6). alp 6 38.5
ppm.
[Ph3PAu(6-MP)].EtOH (3) Yield 64 %, m. p. 250-252C (dec.), Lit. [17] 254- 255 C.
Biological evaluations: The cytotoxieity of 1 3 and a series of common anti-tumor agents was
evaluated in the following human rumor cell lines: MCF7 (breast cancer), EVSA-T (breast cancer),
WlDR (colon cancer), IGROV (ovarian cancer), M19 MEL (melanoma), A498 (renal cancer) and
H226 (non-small cell lung cancer). The MCF7 cell line is estrogen receptor (ER)+/progesterone
receptor .(PR)+ and the cell line EVSA-T is (ER)d(PgR)-. Prior to the experiments a mycoplasma test
was cameo out on all cell lines and found to be negative. All cell lines were maintained in a
continuous logarithmic culture in RPMI 1640 medium with Hepes and phenol red. The medium was
supplemented with 10% FCS, penicillin 100 IU/ml and streptomycin 100 tg/ml. The cells were mildly
trypsinized for passage and for use in the experiments.
Chemicals. RPMI and FCS were obtained from Life technologies (Paisley, Scotland). SRB, DMSO,
penicillin and streptomycin were obtained from Sigma (St Louis MO, USA), trichloroacetic acid and
acetic acid from BakerBV (Deventer, NL) and PBS from NPBI BV (Emmer-Compaseuum, NL).
Experimental procedures. The test and reference compounds were dissolved to a concentration of
250000 ng/ml in full medium, by 20-fold dilution of a stock solution, which contained mg of
compound/200 lxl. The compounds were dissolved in DMSO. Cytotoxieity was estimated by the
microcultuer sulforhodamine B (SRB) test [18].
Cytotoxicity. The experiment was started on day 0 when 150 tl of trypsinized tumor cells (1500
2000 cells/well) were plated in 96-wells flatbottom microtiter plates (falcon 3072, BD). The plates
were preineubated 48 h at 37 C, 8.5 % CO2 to allow the cells to adhere. On day 2, a 3-fold dilution
sequence of ten steps was made in full medium, starting with the 250000 ng/ml stock solution. Every
dilution was used in quadruplicate by adding 50 pl to a column of four wells. This results in a highest
concentration of 62500 ng/ml present in column 12. Column 2 was used for the blank. To column 1,
PBS was added to diminish interfering evaporation. On day 7 the incubation was terminated by
washing the plate twice with PBS. Subsequently, the cells were fixed with 10 % trichloroacetic acid in
PBS and placed at 4 C for h. After 5 washings with tap water, the cells were stained for at least 15
min with 0.4% SRB dissolved in 1% acetic acid. After staining the cells were washed with 1% acetic
acid to remove the unbound stain. The plates were air-dried mad the bound stain was dissolved in 150
tl 10 mM Tris-base. The absorbance was read at 540 nm using an automated microplate reader
(Labsystems Multiskan MS). Data were for construction of concentration-response curves and
determination of the IDs0 value by use of Deltasoft 3 software.
Crystallography: Crystals of [Cy3PAu(SC(O)Ph)] (1) and [PhaPAu(6-MP)].EtOH (3) were obtained
from the slow evaporation of ethanol/chloroform solution of the respective compound. Relevant
crystallographic data is collected in Table 1. Data were collected at 173 K on a Rigaku/MSC Mercury
CCD area detector and the weighting scheme was of the form l/[o2(Fo)]. For 3, H atoms involved in
intermolecular hydrogen bonding were located from a difference map and included in the model.
Table 1. Crystal data for [Cy3PAu(SC(O)Ph)] (1) and [PhaPAu(6-MP)].EtOH (3)
1 3
Formula C2sHaaAuOPS C25H4AuN4OPS
Formula weight 614.6 656.5
Crystal size, mm 0.10 x 0.30 x 0.40 0.20 x 0.20 x 0.20
Crystal system triclinic monoelinic
Space group Pbarl P2/n
a, A 9.091(5) 8.7178(2)
b, A 11.441(5) 27.539(1)
c, A 12.559(4) 10.6542(7)
a o 73.95(2) 90
3, 83.98(5) 107.84(1)
r
o 88.63(11) 90
V, A 3 1248.4(9) 2434.8(2)
Z 2 4
(Mo-Kc0, cm- 1 60.74 62.40
Dealed, g cm-3 1.635 1.791
F(000) 612 1280
0x,
o 30.9 26.6
Reflns meas, unique,R 14092, 5953, 0.023 24146, 5113, 0.046
Reflns with I 3.0o(1) 5314 3507
Refined parameters 262 298
R(F), wR(lO 0.0"21, 0.025 0.025, 0.024
p, e A-3 0.73 2.11
Programs used CrystalClear 19], teXsan [20], DIRDIF [21], ORTEP [22]
Deposition number CCDC 158867 CCDC 158866
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Results and Di#cu#sion
Characterization of I and 2: The major feature of interest in the solid state IR spectra (KBr disks)
related to e shift of v(C=O) from 1681 cm
4 in the acid to 1620 (1) and 1611 (2) cm
4 for the
complexes. The 1H and 13C resonances were assigned on the basis of the interpretation of their
Heteronuclear Multiple Quantum Coherence (HMQC) and Heteronuelear Multiple Bond Connectivity
(HMBC) spectra. Upon eomplexation, resonances due to H3 are shifted downfield compared to that
for the uncoordinated acid, i.e. 5 7.90 ppm. By contrast, for I resonances due to H4 and H5 are shifted
marginally upfield compared to the free ligand (i.e. 7.47 and 7.61 ppm, respectively); these
resonances were obscured for 2. Upon complexation, there is no significant shift in the laC resonances
ascribed to C3-C5. However, the respective resonances due to C1 and C2 are shifted downfield y
approximately 10 and 6 ppm, respectively compared to the free ligand. Small shifts in the 3P
resonances, compared to the RaPAuC1 precursors, provide further evidence for complexation. Crystals
of I were obtained allowing for a full structure determination by X-ray crystallographic methods.
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Figure 2. Molecular structure (50% probability ellipsoids) of [Cy3PAu(SC(O)Ph)] (1). Selected bond
distances and angles: Au-S(1) 2.325(2), Au-P(1) 2.279(1), S(1)-C(1) 1.776(4), O(1)-C(1) 1.217(4) A;
S(1)-Au-P(1) 176.46(3), Au-S(1)-C(1) 102.24(11), S(1)-C(1)-O(1) 123.1(3).
The molecular structure of I is shown in Figure 2 and selected geometric parameters are collected in
the Figure caption. The gold atom exists in the expected linear geometry defined by the S and P donor
atoms. As is usual for complexes of this type, the Au-S distance is longer than the Au-P distance. This
pattern of bond distance variation coupled with length of the C-S distance indicates that the ligand is
functioning as a thiolate. There is a small deviation from the ideal linear geometry may be due to the
close approach of the carbonyl oxygen atom. The Au...O separation is 3.197(3) A, a distance
resembling those found in related systems [23, 24]. Although full details are not reported here owing
to high residual electron density peaks, a preliminary investigation of the structure of 2 revealed a
similar coordination pattern as that reported for 1. The molecular structure of 3, [Ph3PAu(6-
MP)].EtOH, has also been determined.
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Figure 3. Molecular structure (50% probability ellipsoids) of [PhaPAu(6-MP)].EtOH (3). Selected
bond distances and angles: Au-S(6) 2.311(2), Au-P(1) 2.258(1), S(6)-C(6) 1.739(5) .3,; S(6)-Au-P(1)
171.17(4), Au-S(6)-C(6) 105.6(2).
Characterization of 3: [Ph3PAu(6-MP)].EtOH (3) was also prepared in order to provide another
reference compound for the cytotoxicity screening as 3 has been the subject of several investigations in
this context [10 13]. During purification of the compound crystals were isolated and found to
represent a second polymorphic form for this compound. The molecular structure, Figure 3, is m
essential agreement with that found in the triclinic modification [17].
The interatomic parameters in the two polymorphs are equal within experimental error. By contrast,
there are some small but significant differences in bond angles so that in the present structure the S(6)-
Au-P(1) and Au-P(1)-C(11) bond angles of 171.17(4) and 114.4(2), respectively may be compared to
173.71(6) and 114.2(2) in the trielinic polymorph [17]. The Au/S(1)/C(6)/C(5) torsion angle of
3.6(5) facilitates the close approach of the N(7) atom to gold such that the separation between them is
2.889(4) A. This distance is within the sum of the van der Waals radii for these atoms of 3.25 A [25].
The crystal lattice of 3 features intermolecular hydrogen-bonding interactions as illustrated in Figure 4.
As can be seen from Figure 4, translationally related molecules are linked via ethanol molecules of
crystallization. The ethanol molecule forms a donor interaction via OH(4) to a N(1)’ atom so that
H(4)...N(1)’ is 1.82 A, O(4)...N(1)’ is 2.750(6) A and the angle subtended at H(4) is 168; symmetry
operation: x-l, y, z. An acceptor interaction is also formed to N-H(7) with H(7)... 0(4) 1.69 A,
N(7)... 0(4) 2.732(5) A and N(7)-H(7)...O(4) of 172. In this way, molecules are linked to form
chains aligned along the crystallographic a-direction.
Cytotoxicity: The new compounds 1 and 2, the known anti-tumor compound 3 and several standards
were screened for cytotoxicity in a panel of human cancer lines as detailed in the Experimental section.
Results of the screen are summarized in Table 2.
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Figure 4. Molecular aggregation in the structure of [PhAu(6-MP)].EtOH (3).
Table 2. Cytotoxicity data (IDs0, ng/ml) for [CyaPAu(SC(O)Ph)] (1), [PhsPAu(SC(O)Ph)] (2),
[Ph3PAu(6-MP)].EtOH (3) and established cytotoxic agents
Cmpound’ A98 EVsA-T H226 iGROV M19 MCFL7 WIDR
(1) 4358 3319 6293 2916 2805 2805 5135
(2) 954 826 1124 324 1031 1010 942
(3) 1236 456 738 347 91.5 943 1200
cisplatin 2253 422 3269 169 558 699 967
DOXb 90 8 199 60 16 10 11
5-FUb 143 475 340 297 442 750 225
MTXb 37 5 2287 7 23 18 < 3.2
ETO
b 1314 317 3934 580 505 2594 150
TAXb < 3.2 < 3.2 < 3.2 < 3.2 < 3.2 < 3.2 < 3.2
S Experimeatal fcr deiails of cell lines.
Abbreviations: DOX doxorubicin, 5-FU 5-fluorouracil, MTX methotrexate, ETO etoposide, TAX
taxol.
Of the thiobenzoate compounds 1 and 2, the triphenylphosphine compound was tmiformatly more
active than the cyclohexylphosphine. This result is in contrast to the conclusions of earlier studies on
related systems that suggest that compounds containing cyelohexylphosphine are the more potent [13].
The known anti-tumour compound 3 had comparable activity to that of 2. The two triphenylphosphine
derivatives were more active than cisplatin in the A498 and H226 cell lines and had comparable or
reduced potency in the remaining cell lines. Thus, it may be concluded that while the gold-containing
compounds examined had good to high cytotoxcity, they were not as active as cisplatin in all human
cell lines.
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